Drug/Small Molecule:
omeprazole

last updated 08/10/2011

Dutch Pharmacogenetics Working Group Guideline for omeprazole and CYP2C19

Summary

For CYP2C19 ultrarapid metabolizers, be extra alert to insufficient response and consider increasing omeprazole dose by 100-200%.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on CYP2C19 genotype [Article:21412232]. For the CYP2C19 UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 100-200%.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
CYP2C19 PM (*2/*2, *2/*3, *3/*3) None Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints Positive clinical effects
CYP2C19 IM (*1/*2, *1/*3, *17/*2, *17/*3) None Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints Positive clinical effects
CYP2C19 UM (*17/*17) Helicobacter pylori eradication: increase dose by 100-200%. Be extra alert to insufficient response
Other: be extra alert to insufficient response. Consider dose increase by 100-200%
Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints Minor clinical effect (statistically significant difference): QTc prolongation (<450 ms female, <470 ms male); international normalized ratio increase < 4.5
Kinetic effect (statistically significant difference)

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency, Japan (PMDA). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

Sources:

  • FDA Information is gathered from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" and from FDA-approved labels brought to our attention. Please note that drugs may be removed from or added to the FDA's Table without our knowledge. We periodically check the Table for changes and update PharmGKB accordingly. Drugs listed on the Table to our knowledge are tagged with the Biomarker icon. A drug label that has been removed from the Table will not have the Biomarker icon but will continue to have an annotation on PharmGKB stating the label has been removed from the FDA's Table. We acquire label PDF files from DailyMed.
  • EMA European Public Assessment Reports (EPARs) that contain PGx information were identified from [Article:24433361] and also by searching for drugs for which we have PGx-containing FDA drug labels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for omeprazole and CYP2C19

Informative PGx

Summary

Omeprazole is an inhibitor of CYP2C19 enzyme. Avoid concomitant use of clopidogrel and omeprazole. 

Annotation

Omeprazole is indicated for short-term treatment of duodenal and gastric ulcer in adults and treatment of gastroesophageal reflux disease. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.

Excerpts from the omeprazole (Prilosec) label:

Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. Omeprazole is an inhibitor of CYP2C19 enzyme.

Avoid concomitant use of omeprazole with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that inhibit CYP2C19 activity. Concomitant use of clopidogrel with 80 mg omeprazole reduces the pharmacological activity of clopidogrel, even when administered 12 hours apart. When using omeprazole, consider alternative anti-platelet therapy.

Drugs which induce CYP2C19 or CYP3A4 (such as St John's Wort or rifampin) can substantially decrease omeprazole concentrations.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the omeprazole (Prilosec) drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Gastroesophageal Reflux
    • Indications & usage section
    • source: PHONT
  • HIV Infections
    • Warnings section
    • source: PHONT
  • Peptic Ulcer
    • Indications & usage section
    • source: PHONT
  • CYP2C19
    • Drug interactions section, Pharmacokinetics section, Warnings and precautions section, metabolism/PK
    • source: FDA Label
  • CYP3A4
    • Drug interactions section
    • source: FDA Label

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
Roche AmpliChip CYP450 Test Variant in CYP2C19
Luminex xTAG CYP2C19 CYP2C19*1, CYP2C19*10, CYP2C19*17, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*9
Spartan RX CYP2C19 System CYP2C19*17, CYP2C19*2, CYP2C19*3 , rs12248560 , rs4986893 , rs4244285

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all omeprazole variant annotations

Gene ? Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP No VIP available No VIP available CYP1A2 *1F N/A N/A N/A
No VIP available CA VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1A N/A N/A N/A
No VIP available CA VA CYP2C19 *1B N/A N/A N/A
No VIP available CA VA CYP2C19 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *2A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2B N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2C N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2D N/A N/A N/A
No VIP available CA VA CYP2C19 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *3A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *8 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *9 N/A N/A N/A
No VIP available CA VA CYP2C19 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *11 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *13 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *15 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *16 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *18 N/A N/A N/A
No VIP available CA VA CYP2C19 *19 N/A N/A N/A
No VIP available CA VA CYP2C19 *26 N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 extensive metabolizers
CYP2C19 extensive metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available CA VA
rs11188072 -3402, 1599C>T, 47323525C>T, 96519061C>T, CYP2C19:, CYP2C19: -3402C>T, part of CYP2C19*17
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1143634 113590390G>A, 315C>T, 3339053G>A, 8967C>T, Phe105=
G > A
Synonymous
Phe105Phe
No VIP available CA VA
rs12248560 -806C>A, -806C>T, 4195C>A, 4195C>T, 47326121C>A, 47326121C>T, 96521657C>A, 96521657C>T, CYP2C19*17, CYP2C19*17 CYP2C19: -806C>T, CYP2C19: -806C>T
C > T
C > A
5' Flanking
No VIP available CA VA
rs16944 -598T>C, 113594867A>G, 3343530A>G, 4490T>C, IL1B: -511 C/T
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1799724 *1012C>T, -1037C>T, 2828023C>T, 2836120C>T, 2873283C>T, 2885366C>T, 2922188C>T, 3052098C>T, 31482482C>T, 31542482C>T, 4133C>T, 7607C>T, TNF:-850C-T, TNF:-857 C/T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs1799964 *838T>C, -1211T>C, -1834A>G, -1836A>G, 2827849C>C, 2835946C>C, 2873109T>C, 2885192T>C, 2922014C>C, 3051924T>C, 31482308T>C, 31542308T>C, 3959T>C, 7433T>C, TNF: -1031 T/C, TNF: ¿1031 T/C, TNF:¿1031 T/C
T > C
5' Flanking
rs4244285 24154G>A, 24154G>C, 47346080G>A, 47346080G>C, 681G>A, 681G>C, 96541616G>A, 96541616G>C, CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, Pro227=
G > A
G > C
Synonymous
Pro227Pro
rs4986893 22948G>A, 47344874G>A, 636G>A, 96540410G>A, CYP2C19*3, CYP2C19:636G>A, CYP2C19:G636A, Trp212Ter
G > A
Stop Codon
Trp212null
No VIP available No Clinical Annotations available VA
rs55948420 1180G>A, 47414168G>A, 92242G>A, 96609704G>A, Val394Met
G > A
Missense
Val394Met
No VIP available No Clinical Annotations available VA
rs75519181
A > G
Missense
Asn487Asp
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • OMEP
  • OMP
  • OMZ
  • Omeprazol [INN-Spanish]
  • Omeprazole magnesium
  • Omeprazolum [INN-Latin]
  • omeprazole
Trade Names
  • Antra
  • Audazol
  • Aulcer
  • Belmazol
  • Ceprandal
  • Danlox
  • Demeprazol
  • Desec
  • Dizprazol
  • Dudencer
  • Elgam
  • Emeproton
  • Epirazole
  • Erbolin
  • Exter
  • Gasec
  • Gastrimut
  • Gastroloc
  • Gibancer
  • Indurgan
  • Inhibitron
  • Inhipump
  • Lensor
  • Logastric
  • Lomac
  • Losec
  • Mepral
  • Miol
  • Miracid
  • Mopral
  • Morecon
  • Nilsec
  • Nopramin
  • Ocid
  • Olexin
  • Omapren
  • Omebeta 20
  • Omed
  • Omegast
  • Omepral
  • Omeprazon
  • Omeprol
  • Omesek
  • Omezol
  • Omezolan
  • Omid
  • Omisec
  • Omizac
  • Ompanyt
  • Ortanol
  • Osiren
  • Ozoken
  • Paprazol
  • Parizac
  • Pepticum
  • Pepticus
  • Peptilcer
  • Prazentol
  • Prazidec
  • Prazolit
  • Prilosec
  • Procelac
  • Proclor
  • Prysma
  • Ramezol
  • Regulacid
  • Sanamidol
  • Secrepina
  • Tedec Ulceral
  • Ulceral
  • Ulcesep
  • Ulcometion
  • Ulcozol
  • Ulcsep
  • Ulsen
  • Ultop
  • Ulzol
  • Victrix
  • Zefxon
  • Zegerid
  • Zepral
  • Zimor
  • Zoltum
Brand Mixture Names

PharmGKB Accession Id:
PA450704

Description

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells.

Source: Drug Bank

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H +/K +-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

Source: Drug Bank

Pharmacology

Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H +/K + ATPase at the secretory surface of the gastric parietal cell. As a result, it inhibits acid secretion into the gastric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take 30-60 minutes before meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Protein Binding

95%

Source: Drug Bank

Absorption

Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.

Source: Drug Bank

Half-Life

0.5-1 hour

Source: Drug Bank

Toxicity

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Urinary excretion is a primary route of excretion of omeprazole metabolites.

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H19N3O3S

Source: Drug Bank

Isomeric SMILES

Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC

Source: OpenEye

Canonical SMILES

COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C

Source: Drug Bank

Average Molecular Weight

345.416

Source: Drug Bank

Monoisotopic Molecular Weight

345.114712179

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Proton Pump Inhibitor Pathway, Pharmacokinetics
    Omeprazole metabolism in the liver.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ATP4A (source: Drug Bank)

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clopidogrel

Drug Interactions

Drug Description
omeprazole Increases the effect of the benzodiazepine (source: Drug Bank)
omeprazole Increases the effect of the benzodiazepine (source: Drug Bank)
omeprazole This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank)
omeprazole This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of cilostazol (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect and toxicity of cyclosporine (source: Drug Bank)
omeprazole Omeprazole increases the effect and toxicity of cyclosporine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of hydantoin (source: Drug Bank)
omeprazole Omeprazole decreases the absorption of indinavir (source: Drug Bank)
omeprazole Omeprazole decreases the absorption of indinavir (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
omeprazole Omeprazole increases the levels of methotrexate (source: Drug Bank)
omeprazole Omeprazole increases the levels of methotrexate (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
alprazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
alprazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
atazanavir This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank)
atazanavir This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank)
chlordiazepoxide Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
chlordiazepoxide Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
cilostazol Omeprazole increases the effect of cilostazol (source: Drug Bank)
clonazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
clonazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
clorazepate Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
cyclosporine Omeprazole increases the effect and toxicity of cyclosporine (source: Drug Bank)
cyclosporine Omeprazole increases the effect and toxicity of cyclosporine (source: Drug Bank)
dasatinib Possible decreased levels of dasatinib (source: Drug Bank)
dasatinib Omeprazole may decrease the serum level of dasatinib. (source: Drug Bank)
diazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
diazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
disopyramide The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
disopyramide The beta-blocker increases toxicity of disopyramide (source: Drug Bank)
enoxacin The agent decreases the absorption of enoxacin (source: Drug Bank)
enoxacin Omeprazole may decrease the absorption of enoxacin. (source: Drug Bank)
estazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
estazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
ethotoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
flurazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
flurazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
fosphenytoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
halazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
indinavir Omeprazole decreases the absorption of indinavir (source: Drug Bank)
indinavir Omeprazole decreases the absorption of indinavir (source: Drug Bank)
itraconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
itraconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
ketazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
mephenytoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
mephenytoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
methotrexate Omeprazole increases the levels of methotrexate (source: Drug Bank)
methotrexate Omeprazole increases the levels of methotrexate (source: Drug Bank)
midazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
midazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
phenytoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
phenytoin Omeprazole increases the effect of hydantoin (source: Drug Bank)
prazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
quazepam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
triazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
triazolam Omeprazole increases the effect of benzodiazepine (source: Drug Bank)
voriconazole Voriconazole increases the effect and toxicity of omeprazole (source: Drug Bank)
voriconazole Voriconazole increases the effect and toxicity of omeprazole (source: Drug Bank)
omeprazole Omeprazole increases the effect of hydantoin (source: Drug Bank)
omeprazole Omeprazole increases the effect of hydantoin (source: Drug Bank)
omeprazole Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered. (source: Drug Bank)
omeprazole Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response. (source: Drug Bank)
omeprazole Omeprazole increases the effect of the benzodiazepine (source: Drug Bank)
omeprazole Omeprazole increases the effect of the benzodiazepine (source: Drug Bank)
omeprazole The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to omeprazole: 105

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. European journal of clinical pharmacology. 2014. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics. 2014. Lima John J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenetics and genomics. 2014. Langaee Taimour Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. The pharmacogenomics journal. 2013. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. American heart journal. 2013. Gurbel Paul A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?. Heart (British Cardiac Society). 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PloS one. 2013. Tang Hui-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. British journal of clinical pharmacology. 2012. Lin Chen-Fang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Wang Huijuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011. Yang Jyh-Chin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. Journal of clinical pharmacy and therapeutics. 2010. Zhang L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation. 2010. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010. Kuo Chao-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. European journal of clinical pharmacology. 2010. Wang Yongqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Alimentary pharmacology & therapeutics. 2010. Hunfeld N G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. British journal of clinical pharmacology. 2010. Li-Wan-Po Alain, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical pharmacology and therapeutics. 2010. Dumond J B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kearns Gregory L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. The pharmacogenomics journal. 2010. Gebeyehu E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug metabolism and disposition: the biological fate of chemicals. 2009. Lee Su-Jun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. Journal of clinical pharmacology. 2009. Chen B L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. Journal of clinical pharmacy and therapeutics. 2009. Jin S K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochemical pharmacology. 2008. Cui Xiaoming, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clinical pharmacology and therapeutics. 2008. Myrand S P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic & clinical pharmacology & toxicology. 2008. Hanioka Nobumitsu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochemical pharmacology. 2008. Yoshinari Kouichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. British journal of clinical pharmacology. 2008. Hunfeld Nicole G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. British journal of clinical pharmacology. 2008. Baldwin R Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clinical pharmacology and therapeutics. 2008. Singh K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Digestive diseases and sciences. 2008. Ando Takashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug metabolism and disposition: the biological fate of chemicals. 2008. Foti Robert S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug metabolism and disposition: the biological fate of chemicals. 2008. Lu Chuang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Proton pump inhibitors: an update of their clinical use and pharmacokinetics. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008. Zhao Fujun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clinical pharmacology and therapeutics. 2007. Ryu J Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007. Furuta Takahisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica; the fate of foreign compounds in biological systems. 2007. Hanioka N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cellular signalling. 2006. Gerbal-Chaloin Sabine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical pharmacology and therapeutics. 2006. Sim Sarah C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clinical pharmacology and therapeutics. 2006. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clinical pharmacology and therapeutics. 2006. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. International journal of clinical pharmacology and therapeutics. 2006. Klotz U. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. The American journal of gastroenterology. 2006. Padol Sara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Alimentary pharmacology & therapeutics. 2005. Ohkusa T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals. 2005. Koyano Satoru, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. European journal of clinical pharmacology. 2005. Gawrońska-Szklarz Barbara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). The Journal of biological chemistry. 2004. Burk Oliver, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. Basic & clinical pharmacology & toxicology. 2004. Roh Hyung-Keun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Alimentary pharmacology & therapeutics. 2003. Shimatani T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. Pharmacogenetics. 2003. Arefayene Million, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. The American journal of gastroenterology. 2003. Take Susumu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. The American journal of gastroenterology. 2003. Sapone A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. British journal of clinical pharmacology. 2002. Han Xing-Mei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. Journal of gastroenterology and hepatology. 2002. Inaba Tomoki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. Pharmacogenetics. 2002. Lutz Markus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-drug interaction in pharmacogenetics and pharmacogenomics. Rinsho byori. The Japanese journal of clinical pathology. 2002. Ozawa Shogo. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. The Journal of pharmacology and experimental therapeutics. 2002. Raucy Judy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chemico-biological interactions. 2001. Lu C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clinical pharmacology and therapeutics. 2001. Furuta T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2001. Dojo M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. Journal of gastroenterology and hepatology. 2001. Miyoshi M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The proton-pump inhibitors: similarities and differences. Clinical therapeutics. 2000. Horn J. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology. 2000. Sagar M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology. Pharmacoepidemiology and drug safety. 2000. Clark D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clinical pharmacology and therapeutics. 1999. Tanigawara Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Populations and genetic polymorphisms. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 1999. Weber W W. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Annals of internal medicine. 1998. Furuta T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug metabolism and disposition: the biological fate of chemicals. 1997. Ko J W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Clinical pharmacology and therapeutics. 1997. Sohn D R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995. Chang M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. The Journal of pharmacology and experimental therapeutics. 1994. Curi-Pedrosa R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clinical pharmacology and therapeutics. 1992. Rost K L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical pharmacology and therapeutics. 1990. Andersson T, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
63739-358-10
DrugBank:
DB00338
ChEBI:
7772
KEGG Compound:
C07324
KEGG Drug:
D00455
PubChem Compound:
4594
PubChem Substance:
189970
46509065
Drugs Product Database (DPD):
2260867
BindingDB:
50241343
ChemSpider:
4433
Therapeutic Targets Database:
DAP000180
FDA Drug Label at DailyMed:
0dc9682c-a4ae-4786-8dd9-31e33ce9861b

Clinical Trials

These are trials that mention omeprazole and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.